Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
MWN-AI** Summary
Shineco, Inc. (NASDAQ: SISI), a pioneer in induced pluripotent stem cell (iPSC) technology, has partnered with Singapore-based BICC Pte Ltd to enhance the integration and application of "on-chain cell assets" across various sectors. This collaboration represents a significant evolution from technical integration to real-world applicability within the Real World Asset (RWA) ecosystem. The partnership aims to establish a robust cross-enterprise redeemability framework, allowing users to redeem "Cell Reimbursement Vouchers" linked to compliant stem cell assets across designated BICC scenarios.
Shineco's initiatives, including launching a Cell Digital Division and acquiring a majority stake in Xi'an Dong'ao Health Management, have laid the groundwork for digital applications in cell asset management. Under this new partnership, BICC will integrate its iPSC storage services into Shineco's blockchain infrastructure, streamlining the verification and delivery of cell therapy services through BICC’s extensive sales network in Asia.
The two firms emphasize a division of responsibilities for effective operations: Shineco will focus on maintaining high-quality cell standards and refining offline network logistics, while BICC will enhance user services and integration of scenarios. This structure is designed to ensure compliant management from asset storage to application, fully aligning with local regulations.
Jennifer Zhan, CEO of Shineco, expressed enthusiasm for the collaboration, highlighting the transition from a technical service model to a comprehensive cell economy infrastructure provider. This partnership not only aims to refine and validate the clinical applications of stem cell technologies but also strives to encourage more entities to join this emerging ecosystem, ultimately contributing to long-term growth and innovation in the biotech sector.
MWN-AI** Analysis
Shineco (NASDAQ: SISI) has recently made significant strides in the emerging Real World Asset (RWA) ecosystem through a strategic cooperation with BICC Pte Ltd. This partnership focuses on integrating induced pluripotent stem cell (iPSC) technology with blockchain, aiming for cross-enterprise redeemability of cell assets. Given the innovation at play, investors should consider Shineco as a potential growth opportunity.
The partnership enables the issuance of "Cell Reimbursement Vouchers" on Ethereum, creating a digital identity system for cell assets that enhances transactional efficiency. The collaboration with BICC also leverages its vast distribution network, providing crucial offline support that aligns with Shineco’s aims to streamline the delivery of stem cell services. This synergy not only addresses inefficiencies in traditional services but is positioned to capture a broader market share within the lucrative health tech landscape.
Moreover, Shineco’s comprehensive infrastructure, including its recent acquisition of a healthcare management firm, paves the way for enhanced standardization and compliance—a critical factor for the adoption of blockchain technologies. As the company transitions from a purely technical service provider to a more integrated global player, its potential for long-term growth becomes increasingly compelling.
Investors should note that while the growth prospects appear strong, they must remain cautious of potential regulatory challenges and the competitive nature of the biotechnology sector. It’s important to monitor ongoing project developments and market trends closely. Overall, Shineco represents an intriguing proposition, particularly for those looking to invest in the intersection of biomedicine and technological innovation. Diversifying investment portfolios to include such innovative biotechnology firms could yield substantial benefits as the industry matures.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
PR Newswire
BEIJING , Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore -based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application.
This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management Co., Ltd. These efforts lay a solid foundation for the digital application of cell assets. The two parties will collaborate on standard-setting, compliance coordination, and scenario exploration to transition the project from "technical feasibility" to "verifiable applicability."Under the cooperation framework, Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating"digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." Following the collaboration with BICC, BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system. Users holding" Cell Reimbursement Vouchers" will be able to redeem them in designated BICC scenarios, forming a cross-enterprise service
On the offline support front, Shineco has established a "storage + reinfusion" network through the acquisition of Xi'an Dong'ao Health (specializing in stem cell/immune cell storage and health management). BICC's distribution network (3,000+ sales representatives) will serve as extended nodes of this network, allowing users to complete voucher verification and cell therapy services at BICC's Asian service centers. This addresses the inefficiencies of traditional cross-regional cell service circulation. Additionally, BICC's clinically validated wound-healing solutions, serum-free media patents, cell banking services, iPSC-derived therapies and exosome delivery technology will synergize with Shineco's extracellular vesicle-derived products business, with technical parameters incorporated into the blockchain asset valuation system to enhance the technical endorsement of on-chain assets.
In terms of division of responsibilities, Shineco will focus on cell quality and offline network standardization, while BICC will emphasize user services and scenario integration. Both parties will collaborate with technical partners to adapt on-chain modules and compliance tools, ensuring all initiatives strictly adhere to local regulations and internal risk controls. Shineco assumes full responsibility for cell quality, Plus Me ensures on-chain compliance, and BICC contributes its scientist team and medical resources to participate in standardizing cell assets. The three parties will ensure end-to-end compliance for on-chain cell assets—from storage and circulation to application supporting Shineco's vision of "building a decentralized biological cell marketing ecosystem."
Jennifer Zhan , CEO of Shineco, stated, "The collaboration with BICC will tightly integrate 'standards and scenarios,' exploring verifiable application paths within a compliance framework. Shineco is transitioning from a single technical service provider to a global cell economy infrastructure provider. We welcome more biological cell companies to join the ecosystem and will continue to update on project progress."
About BICC Pte Ltd
Founded in 2024, BICC is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia—including offices in China , Thailand , and Singapore—BICC leverages its proprietary stem cell technologies, such as patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications, alongside personalized cell banking services. This expertise is enhanced by a suite of science-backed wellness offerings, including regenerative treatments, anti-aging supplements, and exosome-based cosmetics, positioning BICC at the cutting edge of integrated health solutions. For more information about BICC, please visit www.BICC.sg .
About Shineco, Inc.
Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/ .
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco,Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
SOURCE Shineco,Inc.
FAQ**
How does the strategic partnership between Shineco Inc. (NASDAQ: SISI) and BICC enhance the process of redeeming "on-chain cell assets" for users, and what specific benefits does this collaboration provide to the RWA ecosystem?
In what ways will Shineco Inc. SISI ensure the quality and compliance of its iPSC technology platforms as it integrates BICC's services into its blockchain system, and what role does Plus Me Limited play in this process?
Given the growing emphasis on compliance and standard-setting in the RWA ecosystem, how does Shineco Inc. SISI plan to adapt and implement local regulations within its operations alongside BICC's expertise?
What are the expected long-term growth prospects for Shineco Inc. (SISI) and BICC as they develop the "decentralized biological cell marketing ecosystem," and how might this impact the overall biotechnology industry?
**MWN-AI FAQ is based on asking OpenAI questions about Shineco Inc. (NASDAQ: SISI).
NASDAQ: SISI
SISI Trading
-18.91% G/L:
$5.53 Last:
24,594 Volume:
$5.78 Open:
